Search PubMed⌕ Search

Biomedical subjects

R Freed

Publications and source records attributed to R Freed.

7 recordsLinked to original sources
PubMed2001

Calcium influx-independent depression of transmitter release by 5-HT at lamprey spinal cord synapses.

1. The mechanisms by which 5-hydroxytryptamine (5-HT) depresses transmitter release from lamprey reticulospinal axons were investigated. These axons make glutamatergic synapses onto spinal ventral horn neurons. 5-HT reduces release at these synapses, yet the mechanisms remain unclear. 2. Excitatory postsynaptic currents (EPSCs) evoked by stimulation of reticulospinal axons were recorded in ventral horn neurons. 5-HT depressed the EPSCs in a dose-dependent manner with an apparent Km of 2.3 microM. 3. To examine the presynaptic effect of 5-HT, electrophysiological and optical recordings were made from presynaptic axons. Action potentials evoked Ca(2+) transients in the axons loaded with a Ca(2+)-sensitive dye. 5-HT slightly reduced the Ca(2+) transient. 4. A third-power relationship between Ca(2+) entry and transmitter release was determined. However, presynaptic Ca(2+) currents were unaffected by 5-HT. 5. Further, in the presence of a K(+) channel blocker, 4-aminopyridine (4-AP), 5-HT left unaltered the presynaptic Ca(2+) transient, ruling out the possibility of its direct action on presynaptic Ca(2+) current. 5-HT activated a 4-AP-sensitive current with a reversal potential of -95 mV in these axons. 6. The basal Ca(2+) concentration did not affect 5-HT-mediated inhibition of release. Although 5-HT caused a subtle reduction in resting axonal [Ca(2+)]i, synaptic responses recorded during enhanced resting [Ca(2+)]i, by giving stimulus trains, were equally depressed by 5-HT. 7. 5-HT reduced the frequency of TTX-insensitive spontaneous EPSCs at these synapses, but had no effect on their amplitude. We propose a mechanism of inhibition for transmitter release by 5-HT that is independent of presynaptic Ca(2+) entry.

4-Aminopyridine↗
PubMed2001

Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids.

To determine predictors for failed reduction of inhaled corticosteroids (ICS), in 50 subjects with well-controlled asthma (age 43.7 [18-69]; 22 males) taking a median dose of 1,000 microg ICS/d (100-3,600 microg/d), ICS were halved every 8 wk. Airway hyperresponsiveness (AHR) to a bronchial provocation test (BPT) with histamine was measured at baseline. AHR to BPT with mannitol, spirometry, exhaled nitric oxide (eNO), and, in 31 subjects, sputum inflammatory cells were measured at baseline and at monthly intervals. Thirty-nine subjects suffered an asthma exacerbation. Seven subjects were successfully weaned off ICS. Using a Kaplan- Meier survival analysis, the significant predictors of a failure of ICS reduction were being hyperresponsive to both histamine and mannitol at baseline (p = 0.039), and being hyperresponsive to mannitol during the dose-reduction phase of the study (p = 0.02). Subjects older than 40 yr of age tended to be at greater risk of ICS reduction failure (p = 0.059). Response to mannitol and percentage sputum eosinophils were significantly greater before a failed ICS reduction than before the last successful ICS reduction, whereas there were no significant differences in symptoms, spirometry, or eNO. These findings suggest that documentation of patient's AHR or sputum eosinophils may be useful in guiding the reduction of ICS doses.

Adolescent↗
PubMed2000

Nedocromil sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects.

Nedocromil sodium inhibits the response to exercise-induced asthma (EIA). Mannitol given as a powder by inhalation is an osmotic stimulus that identifies EIA. We studied the acute effect of nedocromil on airway responsiveness to mannitol in 24 asthmatic subjects. After a control day, nedocromil (8 mg) or its placebo was administered randomized, double blind, 10 min before a challenge with progressively increasing doses of mannitol. Nedocromil inhibited the response to mannitol and there was a significant increase in the dose of mannitol required to cause a 15% reduction in FEV(1) (PD(15)) after nedocromil 409 (316,503) mg compared with placebo 156 (106,229) mg (p < 0.001). In the presence of nedocromil 12 subjects no longer recorded a 15% decrease in FEV(1) in response to mannitol. The remaining 12 required a significantly greater dose of mannitol to achieve a 15% decrease in FEV(1) after nedocromil. Following nedocromil, a plateau in responsiveness to mannitol was observed in 14 subjects. Nedocromil significantly inhibits the responsiveness to inhaled mannitol in asthmatic subjects.

Administration, Inhalation↗
PubMed1998

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Abeta1-42 is a self-associating peptide whose neurotoxic derivatives are thought to play a role in Alzheimer's pathogenesis. Neurotoxicity of amyloid beta protein (Abeta) has been attributed to its fibrillar forms, but experiments presented here characterize neurotoxins that assemble when fibril formation is inhibited. These neurotoxins comprise small diffusible Abeta oligomers (referred to as ADDLs, for Abeta-derived diffusible ligands), which were found to kill mature neurons in organotypic central nervous system cultures at nanomolar concentrations. At cell surfaces, ADDLs bound to trypsin-sensitive sites and surface-derived tryptic peptides blocked binding and afforded neuroprotection. Germ-line knockout of Fyn, a protein tyrosine kinase linked to apoptosis and elevated in Alzheimer's disease, also was neuroprotective. Remarkably, neurological dysfunction evoked by ADDLs occurred well in advance of cellular degeneration. Without lag, and despite retention of evoked action potentials, ADDLs inhibited hippocampal long-term potentiation, indicating an immediate impact on signal transduction. We hypothesize that impaired synaptic plasticity and associated memory dysfunction during early stage Alzheimer's disease and severe cellular degeneration and dementia during end stage could be caused by the biphasic impact of Abeta-derived diffusible ligands acting upon particular neural signal transduction pathways.

Alzheimer Disease↗
PubMed1996

Protecting fibrinogen with rutin during UVC irradiation for viral inactivation.

Fibrinogen solutions were irradiated with UVC (254 nm) to inactivate contaminating viruses. In order to protect fibrinogen during UVC irradiation, 0.5 mM rutin was added prior to UVC exposure and subsequently removed during processing. Viral kill by 0.1 J/cm2 UVC resulted in the following inactivation values (log 10): non-lipid-enveloped viruses: Parvo > or = 5.5; encephalomyocarditis virus > or = 6.5; hepatitis A virus > or = 6.5: lipid-enveloped viruses: human immunodeficiency virus > or = 5.7; vesicular stomatitis virus > or = 5.7. Fibrinogen irradiated with 0.5 mM rutin did not significantly differ from unirradiated material in terms of clot time and breaking strength. In the absence of rutin, UVC irradiation of fibrinogen at similar fluence led to loss of solubility, increased clot time and the cleavage of fibrino-peptides that reacted with dinitrophenyl hydrazine as a test for ketonic carbonyl groups. High-performance liquid chromatography and mass spectrometry data showed that rutin exposed to UVC formed numerous breakdown, oxidation and combinational products. Experiments with 3H-rutin showed that after UVC irradiation, subsequent processing by a C18 resin and alcohol precipitation removed > 99% rutin, representing < 10 ppm rutin in the final fibrinogen preparations. Residual 3H-rutin was not covalently bonded to the fibrinogen. Immunochemical studies with rabbit antisera to UVC irradiated (with rutin) fibrinogen showed the absence of neoimmungens. By all measures, rutin prevents fibrinogen degradation during virucidal UVC irradiation.

Animals↗
PubMed1983

Metabolic requirements for maintenance of the chlortetracycline-labeled pool of membrane-bound calcium in human neutrophils.

Human neutrophils labeled with chlortetracycline (CTC), commonly used as a probe of membrane-bound calcium, release lysosomal enzymes and exhibit a rapid decrease in fluorescence when exposed to the chemotactic peptide fMet-Leu-Phe or the lectin Con A. This decrease has been attributed to the release of calcium from a membrane-associated "trigger pool." The nature of this putative pool has been further characterized by examining the effects of various inhibitors on the CTC fluorescence response and lysosomal enzyme release from stimulated neutrophils. These agents included inhibitors of glycolysis (2-deoxyglucose and iodoacetate), an uncoupler of oxidative- phosphorylation (KCN), and a sulfhydryl inhibitor (N-ethylmaleimide). Resting neutrophils labelled with CTC demonstrated an enhanced decay of baseline fluorescence when exposed to 2-deoxyglucose or iodoacetate. This suggested that the pool of membrane-bound calcium labelled by this probe was maintained by glycolytic metabolism. Furthermore, 2-deoxyglucose and iodoacetate inhibited both the stimulated decrease in CTC fluorescence and lysosomal enzyme release induced by fMet-Leu-Phe and Con A in a time-dependent manner. KCN did not inhibit either response to stimulation, but did retard the recovery of CTC fluorescence observed when fMet-Leu-Phe was used as the stimulus. High concentrations of N-ethylmaleimide (100 microM) completely inhibited both the CTC fluorescence response and lysosomal enzyme release almost immediately; low concentrations of N-ethylmaleimide (30 microM) inhibited lysosomal enzyme release in a time-dependent manner without significantly affecting changes in CTC fluorescence. These results are consistent with the hypothesis that CTC serves as a probe of membrane-bound "trigger" calcium, the release of which is dependent upon intact glycolysis and is a requirement for lysosomal enzyme release.

Adult↗